C. Roger White
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
C. Roger White has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
Geeta Datta
Department of Medicine, University of Alabama at Birmingham Medical Center, Birmingham, AL 35294
8 shared publicationsG. M. Anantharamaiah
Department of Medicine, University of Alabama at Birmingham Medical Center, Birmingham, AL 35294
7 shared publicationsDavid W. Garber
Department of Medicine, University of Alabama at Birmingham Medical Center, Birmingham, AL 35294
4 shared publicationsHimanshu Gupta
Departments of Medicine, University of Alabama at Birmingham, Birmingham, AL
4 shared publicationsMayakonda N. Palgunachari
Department of Medicine, University of Alabama at Birmingham Medical Center, Birmingham, AL 35294
4 shared publicationsZhenghao Zhang
Departments of Medicine, University of Alabama at Birmingham, Birmingham, AL
4 shared publications
Latest Publications
- Open Access
- 1 November 2018
- Published by Elsevier in Journal of Lipid Research
- Vol. 59 (11) , 2075-2083
Novel fatty acyl apoE mimetic peptides have increased potency to reduce plasma cholesterol in mice and macaques
- 1 November 2018
- Published by Elsevier in Journal of Lipid Research
- Vol. 59 (11) , 2075-2083
Open AccessNovel fatty acyl apoE mimetic peptides have increased potency to reduce plasma cholesterol in mice and macaques
- Open Access
- 29 August 2018
- Published by IntechOpen
Estrogen and Mitochondrial Function in Disease
Anecdotal and scientific evidence suggest that the sex hormone estrogen provides significant health benefits in women. Women have higher estrogen levels than men. Circulating estrogen reaches its highest level during the reproductive period and steadily declines with the onset of menopause. The role of estrogen and estrogen receptors in both cellular physiology and pathophysiology has been controversial. Estrogen has anti-inflammatory and anti-oxidant effects, which preserve cell viability during cardiovascular incidents, but it enhances disease progression in the context of breast cancer. Estrogen mediates these responses via activation of estrogen receptor subtypes located in the cell membrane, nucleus, and mitochondrion. Further, transcription of nuclear and mitochondrial genes by estrogen yields products that play an important role in regulating mitochondrial function. Mitochondria are part of a highly dynamic network and undergo fission and fusion, produce cellular energy, adenosine 5′ triphosphate (ATP), and regulate cell death. Herein, we review the cell and receptor specific effects of estrogen on mitochondrial structure, function, and cell death under normal physiological conditions and in the context of cardiovascular disease, inflammation, neurodegeneration, and cancer. Further research is needed to elucidate the specific role of estrogenic control of mitochondria in health and disease.
- 29 August 2018
- Published by IntechOpen
Open AccessEstrogen and Mitochondrial Function in Disease
Anecdotal and scientific evidence suggest that the sex hormone estrogen provides significant health benefits in women. Women have higher estrogen levels than men. Circulating estrogen reaches its highest level during the reproductive period and steadily declines with the onset of menopause. The role of estrogen and estrogen receptors in both cellular physiology and pathophysiology has been controversial. Estrogen has anti-inflammatory and anti-oxidant effects, which preserve cell viability during cardiovascular incidents, but it enhances disease progression in the context of breast cancer. Estrogen mediates these responses via activation of estrogen receptor subtypes located in the cell membrane, nucleus, and mitochondrion. Further, transcription of nuclear and mitochondrial genes by estrogen yields products that play an important role in regulating mitochondrial function. Mitochondria are part of a highly dynamic network and undergo fission and fusion, produce cellular energy, adenosine 5′ triphosphate (ATP), and regulate cell death. Herein, we review the cell and receptor specific effects of estrogen on mitochondrial structure, function, and cell death under normal physiological conditions and in the context of cardiovascular disease, inflammation, neurodegeneration, and cancer. Further research is needed to elucidate the specific role of estrogenic control of mitochondria in health and disease.
- 1 November 2016
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 100, S56
Anti-Inflammatory Effects of Apolipoprotein E Mimetics Peptides in THP-1 Human Macrophages
- 1 November 2016
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 100, S56
Anti-Inflammatory Effects of Apolipoprotein E Mimetics Peptides in THP-1 Human Macrophages
- 1 September 2016
- Published by Elsevier in Chemistry and Physics of Lipids
- Vol. 199, 161-169
High-density lipoprotein, mitochondrial dysfunction and cell survival mechanisms
- 1 September 2016
- Published by Elsevier in Chemistry and Physics of Lipids
- Vol. 199, 161-169
High-density lipoprotein, mitochondrial dysfunction and cell survival mechanisms
- 17 April 2015
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 467 (3) , 517-527
Bioenergetic programming of macrophages by the apolipoprotein A-I mimetic peptide 4F
The apoA-I (apolipoprotein A-I) mimetic peptide 4F favours the differentiation of human monocytes to an alternatively activated M2 phenotype. The goal of the present study was to test whether the 4F-mediated differentiation of MDMs (monocyte-derived macrophages) requires the induction of an oxidative metabolic programme. 4F treatment induced several genes in MDMs that play an important role in lipid metabolism, including PPARγ (peroxisome-proliferator-activated receptor γ) and CD36. Addition of 4F was associated with a significant increase in FA (fatty acid) uptake and oxidation compared with vehicle treatment. Mitochondrial respiration was assessed by measurement of the OCR (oxygen-consumption rate). 4F increased basal and ATP-linked OCR as well as maximal uncoupled mitochondrial respiration. These changes were associated with a significant increase in ΔΨm (mitochondrial membrane potential). The increase in metabolic activity in 4F-treated MDMs was attenuated by etomoxir, an inhibitor of mitochondrial FA uptake. Finally, addition of the PPARγ antagonist T0070907 to 4F-treated MDMs reduced the expression of CD163 and CD36, cell-surface markers for M2 macrophages, and reduced basal and ATP-linked OCR. These results support our hypothesis that the 4F-mediated differentiation of MDMs to an anti-inflammatory phenotype is due, in part, to an increase in FA uptake and mitochondrial oxidative metabolism.
- 17 April 2015
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 467 (3) , 517-527
Bioenergetic programming of macrophages by the apolipoprotein A-I mimetic peptide 4F
The apoA-I (apolipoprotein A-I) mimetic peptide 4F favours the differentiation of human monocytes to an alternatively activated M2 phenotype. The goal of the present study was to test whether the 4F-mediated differentiation of MDMs (monocyte-derived macrophages) requires the induction of an oxidative metabolic programme. 4F treatment induced several genes in MDMs that play an important role in lipid metabolism, including PPARγ (peroxisome-proliferator-activated receptor γ) and CD36. Addition of 4F was associated with a significant increase in FA (fatty acid) uptake and oxidation compared with vehicle treatment. Mitochondrial respiration was assessed by measurement of the OCR (oxygen-consumption rate). 4F increased basal and ATP-linked OCR as well as maximal uncoupled mitochondrial respiration. These changes were associated with a significant increase in ΔΨm (mitochondrial membrane potential). The increase in metabolic activity in 4F-treated MDMs was attenuated by etomoxir, an inhibitor of mitochondrial FA uptake. Finally, addition of the PPARγ antagonist T0070907 to 4F-treated MDMs reduced the expression of CD163 and CD36, cell-surface markers for M2 macrophages, and reduced basal and ATP-linked OCR. These results support our hypothesis that the 4F-mediated differentiation of MDMs to an anti-inflammatory phenotype is due, in part, to an increase in FA uptake and mitochondrial oxidative metabolism.
- 1 January 2015
- Published by Springer Nature
- p. 99-118
Regulation of Macrophage Polarity by HDL, Apolipoproteins, and Apolipoprotein Mimetic Peptides
- 1 January 2015
- Published by Springer Nature
- p. 99-118
Regulation of Macrophage Polarity by HDL, Apolipoproteins, and Apolipoprotein Mimetic Peptides
- Open Access
- 1 August 2012
- Published by Elsevier in Journal of Lipid Research
- Vol. 53 (8) , 1576-1587
Preservation of biological function despite oxidative modification of the apolipoprotein A-I mimetic peptide 4F
- 1 August 2012
- Published by Elsevier in Journal of Lipid Research
- Vol. 53 (8) , 1576-1587
Open AccessPreservation of biological function despite oxidative modification of the apolipoprotein A-I mimetic peptide 4F
- Open Access
- 1 September 2010
- Published by Elsevier in Journal of Lipid Research
- Vol. 51 (9) , 2695-2705
The apolipoprotein A-I mimetic peptide 4F prevents defects in vascular function in endotoxemic rats
- 1 September 2010
- Published by Elsevier in Journal of Lipid Research
- Vol. 51 (9) , 2695-2705
Open AccessThe apolipoprotein A-I mimetic peptide 4F prevents defects in vascular function in endotoxemic rats
- 6 November 2009
- Published by Springer Nature
- Vol. 660, 1-4
ApoE Mimetic Peptide Reduces Plasma Lipid Hydroperoxide Content with a Concomitant Increase in HDL Paraoxonase Activity
ApoE mimetic peptide possesses the putative receptor binding domain 141–150 (LRKLRKRLLR) of apoE covalently linked to the class A amphipathic helical peptide 18A. It dramatically reduces plasma cholesterol in dyslipidemic mouse and rabbit models. Recycling of apoE mimetic peptide increases the duration of preβ-HDL formation leading to extended anti-inflammatory and atheroprotective properties.
- 6 November 2009
- Published by Springer Nature
- Vol. 660, 1-4
ApoE Mimetic Peptide Reduces Plasma Lipid Hydroperoxide Content with a Concomitant Increase in HDL Paraoxonase Activity
ApoE mimetic peptide possesses the putative receptor binding domain 141–150 (LRKLRKRLLR) of apoE covalently linked to the class A amphipathic helical peptide 18A. It dramatically reduces plasma cholesterol in dyslipidemic mouse and rabbit models. Recycling of apoE mimetic peptide increases the duration of preβ-HDL formation leading to extended anti-inflammatory and atheroprotective properties.
- 1 August 2009
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 297 (2) , H866-H873
Apolipoprotein A-I mimetic peptide treatment inhibits inflammatory responses and improves survival in septic rats
Systemic inflammation induces a multiple organ dysfunction syndrome that contributes to morbidity and mortality in septic patients. Since increasing plasma apolipoprotein A-I (apoA-I) and HDL may reduce the complications of sepsis, we tested the hypothesis that the apoA-I mimetic peptide 4F confers similar protective effects in rats undergoing cecal ligation and puncture (CLP) injury. Male Sprague-Dawley rats were randomized to undergo CLP or sham surgery. IL-6 levels were significantly elevated in plasma by 6 h after CLP surgery compared with shams. In subsequent studies, CLP rats were further subdivided to receive vehicle or 4F (10 mg/kg) by intraperitoneal injection, 6 h after sepsis induction. Sham-operated rats received saline. Echocardiographic studies showed a reduction in left ventricular end-diastolic volume, stroke volume, and cardiac output (CO) 24 h after CLP surgery. These changes were associated with reduced blood volume and left ventricular filling pressure. 4F treatment improved blood volume status, increased CO, and reduced plasma IL-6 in CLP rats. Total cholesterol (TC) and HDL were 79 ± 5 and 61 ± 4 mg/dl, respectively, in sham rats. TC was significantly reduced in CLP rats (54 ± 3 mg/dl) due to a reduction in HDL (26 ± 3 mg/dl). 4F administration to CLP rats attenuated the reduction in TC (69 ± 4 mg/dl) and HDL (41 ± 3 mg/dl) and prevented sepsis-induced changes in HDL protein composition. Increased plasma HDL in 4F-treated CLP rats was associated with an improvement in CO and reduced mortality. It is proposed that protective effects of 4F are related to its ability to prevent the sepsis-induced reduction in plasma HDL.
- 1 August 2009
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 297 (2) , H866-H873
Apolipoprotein A-I mimetic peptide treatment inhibits inflammatory responses and improves survival in septic rats
Systemic inflammation induces a multiple organ dysfunction syndrome that contributes to morbidity and mortality in septic patients. Since increasing plasma apolipoprotein A-I (apoA-I) and HDL may reduce the complications of sepsis, we tested the hypothesis that the apoA-I mimetic peptide 4F confers similar protective effects in rats undergoing cecal ligation and puncture (CLP) injury. Male Sprague-Dawley rats were randomized to undergo CLP or sham surgery. IL-6 levels were significantly elevated in plasma by 6 h after CLP surgery compared with shams. In subsequent studies, CLP rats were further subdivided to receive vehicle or 4F (10 mg/kg) by intraperitoneal injection, 6 h after sepsis induction. Sham-operated rats received saline. Echocardiographic studies showed a reduction in left ventricular end-diastolic volume, stroke volume, and cardiac output (CO) 24 h after CLP surgery. These changes were associated with reduced blood volume and left ventricular filling pressure. 4F treatment improved blood volume status, increased CO, and reduced plasma IL-6 in CLP rats. Total cholesterol (TC) and HDL were 79 ± 5 and 61 ± 4 mg/dl, respectively, in sham rats. TC was significantly reduced in CLP rats (54 ± 3 mg/dl) due to a reduction in HDL (26 ± 3 mg/dl). 4F administration to CLP rats attenuated the reduction in TC (69 ± 4 mg/dl) and HDL (41 ± 3 mg/dl) and prevented sepsis-induced changes in HDL protein composition. Increased plasma HDL in 4F-treated CLP rats was associated with an improvement in CO and reduced mortality. It is proposed that protective effects of 4F are related to its ability to prevent the sepsis-induced reduction in plasma HDL.